Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
Even Jake Sullivan, former United States president Joe Biden’s national security adviser, said “the Washington Consensus is a promise that was not kept[.]”